Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Lykos Therapeutics Secures $100M In Series A Funding to Propel MDMA Approval for PTSD Treatment
A decade after its founding as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS),lykos Public Benefit Corporation has triumphantly secured over $100 million in a Series A private stock sale. This immense infusion of funds will underpin the final stages of its …